Shots:

• The DSMB recommended the P-I/II clinical trial of AMT-130 in patients with Huntington’s disease, after reviewing safety data from the four patients in the higher-dose cohort
• In Aug’21, the company has completed enrollment in the second, higher-dose cohort in the P-I/II clinical trial of AMT-130 in 14 patients out of which eight patients received treatment with AMT-130 and six patients received imitation surgery for early manifest HD. The company is expected to complete the full enrollment in mid-2022 in the higher-dose cohort
• The company plans to initiate the P-III study of the therapy in the EU and share initial imaging and biomarker data from the US clinical trial at the end of 2021

  | Ref: Globe Newswire | Image: Fd.nl